Isavuconazole Kinetic Exploration for Clinical Practice.

ABSTRACT:

Background

Isavuconazole is a new antifungal prodrug for the treatment of invasive aspergillosis and mucormycosis. As no clear pharmacokinetic-pharmacodynamic relationship has been established for patients, therapeutic drug monitoring is not currently required. However, as isavuconazole is a new drug, clinicians are sometimes sceptical about the exposure achieved in their patients and seek pharmacokinetic exploration. A minimal response consists of determining that the patient's pharmacokinetic profile agrees with profiles reported by Desai et al. using concentrations from the SECURE study.

Methods

Based on one concentration and Desai et al.'s population-pharmacokinetic model, it is possible to estimate a patient's most likely pharmacokinetic profile. If a patient's pharmaco

SUBMITTER: Darnaud L 

PROVIDER: S-EPMC6277320 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature